VERTEX PHARMACEUTICALS INC / MA
For the period ended Nov 2, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 2, 2026 · Filed Nov 2, 2026
Use the contents to explore the available documents and sections.
VRTX$547.09+0.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Additional Earlier Stage R&D Programs
Additional Earlier Stage R&D Programs
Consistent with its overall strategy, Vertex takes a serial innovation approach to all of its programs, with additional assets or approaches across its portfolio.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.